A Phase 1/2 Trial of CV301 in Combination With Anti-PD-1 Therapy Versus Anti-PD-1 Therapy Alone in Subjects With Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs CV 301 (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms MAGNI-lung-01
- Sponsors Bavarian Nordic
- 21 Sep 2017 Planned number of patients changed from 160 to 200.
- 29 Dec 2016 Status changed from not yet recruiting to recruiting, according to Bavarian Nordic media release.
- 23 Jul 2016 Status changed from planning to not yet recruiting.